Organon & Co
STU : 7XP€12.24+0.25%Oct 16 close
Financials
A full-history view is not available for the cash flow statement yet. This is the statement exactly as one filing printed it.
Condensed Consolidated Statements of Cash Flows
USD · reported units. Click a value to inspect its source.
| Reported line item | Jan 1, 2026 to Jun 30, 2026 (current) | Jan 1, 2025 to Jun 30, 2025 |
|---|---|---|
| Statement of Cash Flows [Abstract] | ||
| Cash Flows from Operating Activities | ||
| Net income | ||
| Adjustments to reconcile net income to net cash flows provided by operating activities: | ||
| Depreciation | ||
| Amortization | ||
| Impairment of assets | ||
| Acquired in-process research and development and milestones | ||
| Accretion and changes in fair value in contingent consideration | ||
| Deferred income tax expense (benefit) | ||
| Stock-based compensation | ||
| Unrealized foreign exchange (gain) loss | ||
| Gain on sale of Jada | ||
| Gain on debt repurchase | ||
| Other | ||
| Net changes in assets and liabilities, net of assets acquired | ||
| Accounts receivable | ||
| Inventories | ||
| Other current assets | ||
| Trade accounts payable | ||
| Accrued and other current liabilities | ||
| Income taxes payable | ||
| Other | ||
| Net Cash Flows Provided by Operating Activities | ||
| Cash Flows from Investing Activities | ||
| Capital expenditures | ||
| Proceeds from sale of property, plant and equipment | ||
| Acquired in-process research and development and milestones | ||
| Proceeds from sale of Jada | ||
| Dermavant acquisition, net of cash acquired | ||
| Purchase of product rights and asset acquisition | ||
| Net Cash Flows Provided by (Used) in Investing Activities | ||
| Cash Flows from Financing Activities | ||
| Proceeds from debt | ||
| Repayments of debt | ||
| Employee withholding taxes related to stock-based awards | ||
| Dividend payments | ||
| Net Cash Flows Used in Financing Activities | ||
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | ||
| Net Increase (Decrease) in Cash and Cash Equivalents | ||
| Cash and Cash Equivalents, Beginning of Period | ||
| Cash and Cash Equivalents, End of Period |
36 line items · 2 reported periodsOriginal filing order · parentheses indicate negative amounts
Each column reflects this filing’s presentation. Original line items and period dates are preserved.